Patenting vaccines in Russia and foreign countries

Vaccines are complex subjects of the invention, as they can include several different subjects: antigens as an active ingredient, a composition, use, a method. Upon preparing a patent application it is necessary to take into account a specific of such subjects. Thus, for example, an antigen as a native protein in some cases cannot be patented due to non-novelty as typically, it is disclosed earlier, during research of pathogenic microorganism. Also, the specific requirements are hold to features of an antigen and use thereof as well as compositions comprising them. These requirements can be strongly varied in dependence on laws of the country wherein a patent application is filed. So, if a release of a product into international market, it should be taken into account patent laws of these countries for preparing the patent application for a vaccine for decreasing a risk of grant refusal

Keywords: vaccines, antigens, patent, foreign patenting

References

  1. The method recommendations on revealing, researching and prophylaxis of adverse events after immunization (approved by the Ministry of Health 12.04.2019).
  2. J. O. Josefsberg, B. Buckland. Vaccine process technology//Biotechnol Bioeng. 2012. № 109 (6). P. 1443-60.
  3. N. А. Alpatova, Zh. I. Avdeeva, S. L. Lysikova et al. General characteristics of adjuvants and their mechanisms of action (part 2)//Biopreparations. Prevention, Diagnosis, Treatment. 2021. 21 (1):20-30. (In Russ.)
  4. New technologies of vaccine producing: genetic immunization and «reverse vaccinology». https://yaprivit.ru/o-vaccinah/novye-tehnologii-proizvodstva-vaccin.
  5. An year passed from the moment of the start of priority examination program for application. Rospatent made a list of the most important patented developments for fighting against COVID-19. https://rospatent.gov.ru/ru/news/reyting-razrabotok-covid19.
  6. А. Duel. For pandemic year 248 inventions for fight against COVID were granted patents//Russian gazette. 2021. 26.04.2021.
  7. Rospatent named the most important Russian developments for fight against. https://ria.ru/20210426/koronavirus-1729957846.html.
  8. Smorodintsev Research Institute of Influenza develops a anti-COVID vaccine as in a form of nasal drops or spray. https://spbvedomosti.ru/news/health/nii-grippa-razrabatyvaet-vaktsinu-ot-kovida-v-vide-kapel-ili-spreya-v-nos.
  9. Art. 1350, Civil Code of the Russian Federation, part four, of 24.11.2006, amended in edition of 11.06.2021 № 213-ФЗ.
  10. Rules on compiling, filing and examining of the documents being a base for law actions on state registration of inventions, and forms thereof. Approved by the Ministry of Economic Development of the Russian Federation, the order of 25.05.2016 № 316, in edition of 31 March, 2021.
  11. Requirements to application documents for patent grant for an invention. Approved by the Ministry of Economic Development of the Russian Federation, the order of 25.05.2016 № 316, in edition of 31 March, 2021.
  12. The PCT applicant’s guide, in edition of 01.07.2020.
  13. Patenting of gene and protein sequences: an EU and US perspective. https://www.taylorwessing.com/synapse/ti-patenting-gene-sequences.html.
  14. Patentability of Natural Products in Europe. https://www.finnegan.com/en/insights/blogs/european-ip-blog/patentability-of-natural-products-in-europe.html.
  15. Section 3, Chapter II, The Patents Act, 1970. https://ipindia.gov.in/writereaddata/Portal/ev/sections/ps3.html.
  16. The Influence of the Andean Intellectual Property Regime on Access to Medicines in Latin America. https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=3064&context=faculty_scholarship.
  17. Change in Brazilian industrial property law: Anvisa no longer participates in the processing of patent applications. https://ficpi.org/ip-news/change-brazilian-industrial-property-law-anvisa-no-longer-participates-processing-patent.
  18. It’s time to consider a patent reprieve for COVID vaccines//Nature. 30.03.2021. Р. 7.
  19. S. Mingazov. WSJ: European Union declares the plan alternative to anti-COVID-19 patent waiver//Forbes. 04.06.2021.
  20. M. Grosheva. «Farmasyntez» receives a compulsory licensing for remdesivir//Pharmvestnik. 05.01.2021.

Authors